more

BioRad Laboratories (BIO)

(Delayed Data from NYSE)

$301.92 USD

+5.10 (1.72%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $302.11 +0.19 (0.06%) 6:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum D VGM

Industry Rank:

Top 30% (76 out of 250)

Industry: Medical - Products

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.

DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research Published on April 24,2023

DexCom's (DXCM) first-quarter results likely to reflect rising volumes across all channels.

medical

What's in Store for West Pharmaceutical (WST) in Q1 Earnings?

by Zacks Equity Research Published on April 21,2023

West Pharmaceutical's (WST) first-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

medical

Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research Published on April 21,2023

Robust performance from MyoSure and NovaSure along with increasing contributions from the company's laparoscopic portfolio are expected to have contributed to the Hologic's (HOLX) Q2 reveneus.

IDEXX Laboratories (IDXX) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research Published on April 21,2023

IDEXX Laboratories' (IDXX) first-quarter 2023 results are expected to reflect an impressive performance in the CAG segment despite inflationary impacts.

Will Lower Managed Care Profits Hurt Centene's (CNC) Q1 Earnings?

by Zacks Equity Research Published on April 21,2023

Centene's (CNC) first-quarter results are likely to reflect growth in premiums and lower costs.

Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research Published on April 20,2023

Henry Schein's (HSIC) medical business is expected to have gained from improved U.S. patient traffic to physician offices, ultimate care sites and ambulatory surgical centers.

What's in Store for Edwards Lifesciences (EW) in Q1 Earnings?

by Zacks Equity Research Published on April 20,2023

Continued demand for the HemoSphere monitoring platform and Smart Recovery is likely to have contributed to the Edwards Lifesciences' (EW) Q1 growth.

Baxter (BAX) to Post Q1 Earnings: What's in the Offing?

by Zacks Equity Research Published on April 20,2023

Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

medical

Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research Published on April 20,2023

Quest Diagnostics' (DGX) first-quarter 2023 results are likely to reflect an impressive performance in its non-COVID-19 base business amid inflationary pressure and labor challenges.

Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research Published on April 19,2023

Zimmer Biomet (ZBH) might have faced an upheaval in business, thanks to the global inflationary situation in terms of mounting labor and raw material costs, severe staffing shortages and supply issues.